Time: 5 November 2026 at 3:00 p.m.

Place: Remote meeting in accordance with Chapter 5, Section 16, Subsection 3 of the Finnish Companies Act

Present: The shareholders and their representatives present at or represented at the Meeting as shown in the list of votes confirmed at the Meeting (Appendix 2).

In addition, the Chair of the Board of Directors of Nightingale Health Plc, Leena Niemistö, and the members of the Board of Directors Antti Kangas, Olli Karhi, Ilkka Laurila, Timo Soininen and Teemu Suna, who is also the CEO of the company, were present at the Meeting. Of the company's executive management, Chief Commercial Officer Minja Salmio was also present. In addition, the company's Auditor with principal responsibility, Panu Vänskä, Authorized Public Accountant, the company's lawyer Satu Sirén-Lähdeaho and technical personnel were present at the Meeting.

1 §
Opening of the Meeting

The Chair of the Board of Directors, Leena Niemistö, gave an opening address and opened the Meeting, welcoming the shareholders.

2 §
Calling the Meeting to order

Attorney-at-Law Olli Iirola was elected as the Chair of the Meeting, who appointed Attorney-at-Law Jarkko Hankaa as the secretary of the General Meeting.

The Chair explained the procedures for handling the matters on the agenda of the Meeting. It was also noted that the General Meeting would be held in Finnish, but the CEO's review would be presented in English.

It was noted that the content of the proposals for resolutions made to the General Meeting is set out in the notice to the Meeting published on 1 October 2026.

Appendix 1

It was noted that the shareholders participating in the remote meeting in real time had all shareholder rights in use during the Meeting (such as the right to present questions orally and the right to vote), apart from the EMP-series shareholders who had all other shareholder rights in use except for the right to vote. In addition, it was noted that a written chat function was not in use at the General Meeting.

It was noted that shareholders had been able to participate in the General Meeting also through advance voting in relation to items 7-17. The proposals for resolutions that are subject to the advance voting are deemed to have been presented at the General Meeting as unchanged in accordance with

Chapter 5, Section 16, Subsection 5 of the Companies Act, and the advance votes are taken into account in a possible vote held at the remote meeting also in situations where an alternative proposal for resolution has been made regarding the matter.

It was noted that if a full counting of votes is not carried out in an item, the number of opposing votes, if the item could be voted on without a counter-proposal, as well as the number of blank votes shall be recorded in the minutes in connection with each item. Otherwise, the votes are shown in the summary attached to the minutes.

Appendix 2

It was noted that no technical or other problems or ambiguities related to advance voting or the meeting procedure in general had come to the attention of the company or Innovatics Oy. The shareholders' right to participate and the correctness of the counting of votes can be verified in a manner comparable to the procedures followed at an ordinary general meeting.

3 §
Election of the person to scrutinize the minutes and to supervise the counting of votes

The company's lawyer Satu Sirén-Lähdeaho was elected as the person to scrutinize the minutes and to supervise the counting of votes.

4 §
Recording the legality of the Meeting

According to Section 13 of the Articles of Association, the Annual General Meeting shall be held annually on a date determined by the Board of Directors within six (6) months of the end of the financial period. According to Section 11 of the Articles of Association, the company's financial period is 1 July - 30 June.

According to Section 12 of the Articles of Association, the notice to the General Meeting shall be delivered to the shareholders at the earliest three (3) months and at the latest three (3) weeks before the General Meeting, however, at the latest nine (9) days before the record date of the General Meeting. The notice shall be delivered to the shareholders by a notice published on the company's website or in at least one nationwide daily newspaper determined by the Board of Directors.

It was noted that the notice to the General Meeting (Appendix 1) had been published on the company's website and as a stock exchange release on 1 October 2026.

The General Meeting was noted to have been convened in accordance with the Articles of Association and the Companies Act and to be legal and constitute a quorum.

5 §
Recording attendance at the Meeting and list of votes

It was noted that the prerequisite for participating in the General Meeting and exercising the right to vote at the Meeting was that the shareholder was registered in the company's shareholders' register maintained by Euroclear Nordics Oy on 26 October 2026 and had registered for the General Meeting within the time specified in the notice to the Meeting, i.e. by 29 October 2026 at 4:00 p.m.

It was noted that a holder of nominee-registered shares had the right to participate in the General Meeting by virtue of the shares based on which the shareholder would have been entitled to be registered in the shareholders' register maintained by Euroclear Nordics Oy on 26 October 2026. In addition, it was noted that the participation of a holder of nominee-registered shares required that the shareholder had, on the basis of such shares, temporarily been registered into the shareholders' register maintained by Euroclear Nordics Oy by 2 November 2026 at 10:00 a.m. The registration has been deemed a registration for the General Meeting.

The real-time participation in the remote meeting required in addition that the shareholders had provided their telephone number and/or email address to Innovatics Oy in connection with the registration and within the registration period, so that the shareholders could be sent a participation link and password to participate in the remote meeting.

It was noted that, in accordance with Chapter 5, Section 16, Subsection 5 of the Companies Act, the shareholders who have exercised their right to vote before the Meeting (through advance voting) or who can exercise their right to vote during the remote meeting are deemed to be participating in the Meeting.

According to Section 4 of the Articles of Association, the company has A-series shares, B-series shares and EMP-series shares. Each A-series share carries ten (10) votes and each B-series share carries one (1) vote at a General Meeting. EMP-series shares do not carry the right to vote.

At the commencement of the Meeting, 19 shareholders representing 30,329,352 shares and 196,597,304 votes participated in the Meeting. These figures include both shareholders who have voted in advance and shareholders participating in the General Meeting in real time.

The list of votes as at the commencement of the Meeting was attached to the minutes.

Appendix 3

6 §
Presentation of the Financial Statements, Consolidated Financial Statements, the Report of the Board of Directors and the Auditor's Report for the financial period of 1 July 2025 - 30 June 2026

It was noted that the company's Annual Report, including the Financial Statements, the Consolidated Financial Statements, the Report of the Board of Directors, the Auditor's Report and the Remuneration Report for the financial period of 1 July 2025 - 30 June 2026, has been available on the company's website since 1 October 2026.

CEO Teemu Suna presented to the General Meeting a review of the financial period of 1 July 2025 - 30 June 2026.

The company's Auditor with principal responsibility, Panu Vänskä, Authorized Public Accountant, presented the Auditor's Report to the General Meeting.

It was noted that the Financial Statements, the Consolidated Financial Statements, the Report of the Board of Directors and the Auditor's Report had been presented to the General Meeting.

Appendix 4

7 §
Adoption of the Financial Statements and the Consolidated Financial Statements

It was resolved to adopt the Financial Statements of Nightingale Health Plc for the financial period of 1 July 2025 - 30 June 2026, including the Consolidated Financial Statements.

Appendix 4

8 §
Resolution on the use of the profit shown on the balance sheet and the payment of dividend

It was noted that the Board of Directors has proposed that, based on the balance sheet to be adopted for the financial period of 1 July 2025 - 30 June 2026, no dividend is paid, and that the loss of the financial period is recorded in retained earnings.

It was resolved to approve the proposal of the Board of Directors set out in the notice to the Meeting on the use of the loss shown on the balance sheet and the payment of dividend.

9 §
Resolution on the discharge of the members of the Board of Directors and the CEO from liability

It was noted that the persons who had served as members of the Board of Directors and as CEO were disqualified from the consideration of this matter.

It was resolved to discharge the members of the Board of Directors and the CEO from liability for the financial period of 1 July 2025 - 30 June 2026.

It was noted that in this item, the number of blank votes of shareholders who had voted in advance was 88,475,035.

10 §
Consideration of the Remuneration Report for governing bodies

It was noted that the Remuneration Report of the company's governing bodies for the financial period of 1 July 2025 - 30 June 2026 was published on 1 October 2026 as part of the company's Annual Report and is available on the company's website.

Appendix 4

The Chair of the Meeting presented the key points of the Remuneration Report to the General Meeting.

It was noted that, in accordance with the notice to the Meeting, the Board of Directors proposed approval of the Remuneration Report. Pursuant to the Companies Act, the resolution on the Remuneration Report is advisory.

It was resolved to approve the Remuneration Report of the governing bodies for the financial period of 1 July 2025 - 30 June 2026 in accordance with the proposal of the Board of Directors.

It was noted that in this item, the number of opposing votes of shareholders who had voted in advance was 1,594,480 and the number of abstentions was 4,602,705.

11 §
Resolution on the remuneration of the members of the Board of Directors

It was noted that, in accordance with the notice to the Meeting, the Board of Directors proposed that the Chair of the Board be paid a monthly remuneration of EUR 4,000 and the other members of the Board be paid a monthly remuneration of EUR 2,000.

It was resolved to approve the proposal of the Board of Directors set out in the notice to the Meeting concerning the remuneration of the members of the Board of Directors.

It was noted that in this item, the number of abstentions of shareholders who had voted in advance was 8,643,280.

12 §
Resolution on the number of members of the Board of Directors

According to Section 7 of the Articles of Association, the Board of Directors shall comprise a minimum of three (3) and a maximum of ten (10) ordinary members.

It was noted that, in accordance with the notice to the Meeting, the Board of Directors proposed that the number of members of the Board of Directors is confirmed to be six (6).

It was resolved to approve the proposal of the Board of Directors set out in the notice to the Meeting concerning the number of members of the Board of Directors.

13 §
Election of members of the Board of Directors

According to Section 7 of the Articles of Association, the term of office of the members of the Board of Directors shall always expire at the end of the Annual General Meeting following the election.

It was noted that, in accordance with the notice to the Meeting, the Board of Directors proposed that, until the end of the next Annual General Meeting, the current members of the Board of Directors Antti Kangas, Olli Karhi, Ilkka Laurila, Leena Niemistö, Timo Soininen and Teemu Suna are re-elected as members of the Board of Directors.

It was resolved to approve the proposal of the Board of Directors set out in the notice to the Meeting concerning the election of members of the Board of Directors.

It was noted that in this item, the number of opposing votes of shareholders who had voted in advance was 1,594,480 and the number of abstentions was 4,041,400.

14 §
Resolution on the remuneration of the Auditor

It was noted that, in accordance with the notice to the General Meeting, the Board of Directors proposed that the remuneration of the Auditor is paid in accordance with a reasonable invoice approved by the company.

It was resolved to approve the proposal of the Board of Directors set out in the notice to the Meeting concerning the remuneration of the Auditor.

15 §
Election of the Auditor

According to Section 10 of the Articles of Association, the company shall have an auditor that is an audit firm approved by the Finnish Patent and Registration Office. The term of office of the Auditor shall expire at the end of the Annual General Meeting following the election.

It was noted that, in accordance with the notice to the Meeting, the Board of Directors proposed that Authorized Public Accounting firm PricewaterhouseCoopers Oy is re-elected as the company's Auditor. PricewaterhouseCoopers Oy has informed that it will nominate Panu Vänskä, Authorized Public Accountant, as the company's Auditor with principal responsibility.

It was resolved to approve the proposal of the Board of Directors set out in the notice to the Meeting concerning the election of the Auditor.

16 §
Authorizing the Board of Directors to decide on the repurchase of company's own shares

It was noted that the Board of Directors proposed to the General Meeting that the Board of Directors is authorized to decide on the repurchase of the company's own shares on the following terms and conditions:

By virtue of the authorization, the Board of Directors is entitled to repurchase a maximum of 1,952,643 A-series shares and 4,029,322 B-series shares by using the non-restricted equity of the company. The amounts correspond approximately to 10% of both share series' shares and the total amount to 9.8% of the company's total amount of shares calculated by the amount of shares on the date of publication of the notice to the General Meeting. The shares may be repurchased in one or more lots.

The company's own shares shall be repurchased at the market price prevailing at the time of the repurchase through public trading on the regulated market of Nasdaq Helsinki Ltd or otherwise at a market price. The authorization entitles the Board of Directors to decide on the repurchase also other than in proportion to the shareholdings of the shareholders (directed repurchase).

The shares may be repurchased to be used in the implementation of possible acquisitions or other arrangements within the company's business, to finance investments, to develop the company's financial structure, as part of the implementation of possible incentive schemes of the company and/or otherwise to be kept by the company, transferred or cancelled.

It is proposed that the authorization includes the right of the Board of Directors to decide on other terms and conditions related to the repurchase of the company's own shares. It is proposed that the authorization is valid for 18 months. The authorization revokes the authorization to repurchase the

company's own shares decided by the previous Annual General Meeting on 6 November 2025.

It was resolved to approve the proposal of the Board of Directors set out in the notice to the Meeting concerning the authorization of the Board of Directors to decide on the repurchase of the company's own shares.

It was noted that in this item, the number of abstentions of shareholders who had voted in advance was 825.

17 §
Authorizing the Board of Directors to decide on the share issue and granting of special rights entitling to shares

It was noted that the Board of Directors proposed to the General Meeting that the Board of Directors is authorized to decide on issuing new shares, conveying the company's own shares held by the company and/or granting of special rights referred to in Chapter 10, Section 1 of the Companies Act on the following terms and conditions:

Maximum amount of shares to be issued

By virtue of the authorization, the Board of Directors is entitled to issue and/or convey a maximum of 1,926,217 A-series shares of the company under one or more decisions. The maximum amount corresponds approximately to 10% of the total amount of A-series shares and approximately to 3.2% of the company's total amount of shares calculated by the amount of shares on the date of publication of the notice to the General Meeting. The share issue and shares granted under the special rights are included in the specified maximum amount.

In addition, under the authorization, the Board of Directors is entitled to issue and/or convey a maximum of 4,064,778 B-series shares of the company by one or more decisions. The maximum amount corresponds approximately to 10% of the total amount of B-series shares and approximately to 6.7% of the company's total amount of shares calculated by the amount of shares on the date of publication of the notice to the General Meeting. The share issue and shares granted under the special rights are included in the specified maximum amount.

In addition, by virtue of the authorization, the Board of Directors is entitled to convey a maximum of 577,920 EMP-series shares held by the company under one or more decisions.

The proposed authorization shall revoke the authorization resolved by the Annual General Meeting held on 6 November 2025 concerning the authorization of the Board of Directors to decide on the share issue and granting of special rights entitling to shares.

By virtue of the proposed authorization, the Board of Directors is thus entitled to issue and/or convey no more than 1,926,217 A-series shares and 4,064,778 B-series shares of the company in total. The share issue and shares granted under the special rights are included in the maximum amounts mentioned. In addition, by virtue of the proposed authorization, the Board of Directors is entitled to convey a maximum of 577,920 EMP-series shares held by the company.

Other conditions

The shares may be issued either against payment or without payment and they may also be issued to the company itself. The authorization entitles the Board of Directors to implement the share issue also as a directed issue. The authorization may be used in the implementation of possible acquisitions or other arrangements within the company's business, to finance investments, to develop the company's financial structure, as part of the implementation of possible incentive schemes of the company and/or for other purposes decided by the Board of Directors.

It is proposed that the authorization includes the right of Board of Directors to decide on other terms and conditions of the share issue and granting of special rights referred to in Chapter 10, Section 1 of the Companies Act. It is proposed that the authorization is valid for 18 months.

It was resolved to approve the proposal of the Board of Directors set out in the notice to the Meeting concerning the authorization of the Board of Directors to decide on the share issue and granting of special rights entitling to shares.

It was noted that in this item, the number of abstentions of shareholders who had voted in advance was 825.

18 §
Closing of the Meeting

It was noted that all matters belonging to the Annual General Meeting had been considered and that the minutes of the Meeting will be available to the shareholders on the company's website at the latest on 19 November 2026.

The Chair thanked the shareholders and the company's management and declared the General Meeting closed.

In witness whereof:

Olli Iirola
Chair

Jarkko Hankaa
Secretary

Scrutinized and approved:

Satu Sirén-Lähdeaho
Person to scrutinize the minutes

APPENDICES

Appendix 1	Notice to the General Meeting
Appendix 2	Summary of votes cast in advance voting
Appendix 3	List of votes of the Meeting
Appendix 4	Annual Report of Nightingale Health Plc for the financial period of 1 July 2025 - 30 June 2026, including, among other things, the Financial Statements and the Consolidated Financial Statements, as well as the Auditor's Report and the Remuneration Report for governing bodies for the financial period of 1 July 2025 - 30 June 2026